Bridgepoint to Ask JPMorgan to Advise on Diaverum Future

Bridgepoint Advisers Ltd., a U.K. private-equity firm with more than $12 billion in committed funds, will choose JPMorgan Chase & Co. (JPM) to consider Swedish renal-care provider Diaverum’s future.

Bridgepoint “is close” to completing JPMorgan’s appointment to look at strategic options for Lund-based Diaverum for the next 12 months, James Murray, a spokesman for the firm, said by phone today.

Diaverum provides renal care to more than 20,000 patients at about 250 clinics in 17 countries, including in South America, Australia, Europe and the Middle East, according to information on its website. The company employs 6,900 people and reported sales of 398 million euros ($530 million) in 2011. Companies owned by London-based Bridgepoint employ 72,000 people in more than 40 countries, according to its website.

To contact the reporters on this story: Aaron Kirchfeld in London at; Niklas Magnusson in Stockholm at

To contact the editor responsible for this story: Frank Connelly at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.